CoChat
Sign Up
Cited by 18Tannin, Tannase and Anticancer ActivitiesCancer-related Molecular PathwaysNatural product bioactivities and synthesis

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cinnamtannin B-1 inhibits cell survival molecules and induces apoptosis in colon cancer

Open access
Carriere, Patrick, Kapur, Neeraj, Mir, Hina, Ward, Ashley, Singh, Shailesh·2018·International Journal of Oncology
DOI 10.3892/ijo.2018.4489PMC PMC6086629
Open this paper in CoChat — free accountOpen PDF

Abstract

Colon cancer patients receiving chemotherapy continue to be burdened with therapeutic failure and adverse side effects, yielding a need to develop more effective treatments. The present study investigates Cinnamtannin B-1 (CTB-1) as a potential low-toxicity therapeutic alternative for colon cancer. CTB-1-treated DLD-1, COLO 201 and HCT-116 (WT p53 and p53 null) colon cancer cells and CCD 841 CoN normal colon epithelial cells were assessed for changes in survival using MTT assay. The effects of CTB-1 on cell cycle progression and the apoptosis of colon cancer cells were measured using flow cytometry and/or immunofluorescence. The expression profiles of cell survival molecules, particularly apoptotic proteins, in the colon cancer cells were evaluated following CTB-1 treatment via antibody array, then validated by western blot analysis. Additionally, the potential synergy between CTB-1 and 5-fluorouracil (5-FU), a conventional chemotherapeutic agent used in the treatment of colon cancer, against colon cancer cells was assessed using MTT assay and Calcusyn software. The results revealed that CTB-1 significantly decreased the survival of the DLD-1, COLO 201 and HCT-116 cells in a time and/or dose-dependent manner, with minimal cytotoxicity to normal colon cells. CTB-1 treatment was shown to induce cell cycle arrest and apoptosis of DLD-1 and COLO 201 cells. Of note, CTB-1 modulated the expression of several cell survival molecules, which tend to be deregulated in colon cancer, including p53, a key transcription factor involved in apoptosis. The downstream regulation of Bcl-2 and Bak expression, as well as cytochrome c release into the cytosol, was also observed following CTB-1 treatment. Furthermore, CTB-1 was shown to significantly enhance the potency of 5-FU via a synergistic drug interaction. This study reveals for the first time, to the best of our knowledge, the ability of CTB-1 to decrease the survival of colon cancer cells through pro-apoptotic mechanisms and display synergy with conventional chemotherapy, demonstrating the potential therapeutic benefit of CTB-1 in colon cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ijo.2018.4489

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 62

  1. Siegel, 2017, Cancer Statistics, 2017, CA Cancer J Clin, 67, 7, 10.3322/caac.21387 · DOI · Paper page
  2. Howlader, 2016, SEER Cancer Statistics Review, 1975–2013
  3. Braun, 2011, Balancing the efficacy and toxicity of chemotherapy in colorectal cancer, Ther Adv Med Oncol, 3, 43, 10.1177/1758834010388342 · DOI · Paper page
  4. Hu, 2012, Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer, Am J Clin Oncol, 35, 228, 10.1097/COC.0b013e318210f812 · DOI
  5. Nadeem, 2014, Cost differential among systemic therapies for colon cancer, Ann Surg Oncol, 21, S83
  6. Liu, 2011, The efficacy of chemotherapy in patients with high-grade metastatic colon cancer, Hepatogastroenterology, 58, 1495, 10.5754/hge11082 · DOI
  7. Engstrom, 2009, NCCN Clinical Practice Guidelines in Oncology: Colon cancer, J Natl Compr Canc Netw, 7, 778, 10.6004/jnccn.2009.0056 · DOI
  8. Patel, 2008, Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R, Int J Cancer, 122, 267, 10.1002/ijc.23097 · DOI
  9. Patel, 2010, Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R, Anticancer Res, 30, 319
  10. Chen, 2014, Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer, Nutr Res, 34, 585, 10.1016/j.nutres.2014.06.010 · DOI
  11. Amin, 2009, Perspectives for cancer prevention with natural compounds, J Clin Oncol, 27, 2712, 10.1200/JCO.2008.20.6235 · DOI
  12. Plumb, 1998, Antioxidant properties of catechins and proanthocyanidins: Effect of polymerisation, galloylation and glycosylation, Free Radic Res, 29, 351, 10.1080/10715769800300391 · DOI
  13. Santos-Buelga, 2000, Proanthocyanidins and tannin-like compounds - nature, occurrence, dietary intake and effects on nutrition and health, J Sci Food Agric, 80, 1094, 10.1002/(SICI)1097-0010(20000515)80:7<1094::AID-JSFA569>3.0.CO;2-1 · DOI
  14. Prasad, 2012, Grape proanthocyanidin inhibit pancreatic cancer cell growth in vitro and in vivo through induction of apoptosis and by targeting the PI3K/Akt pathway, PLoS One, 7, e43064, 10.1371/journal.pone.0043064 · DOI
  15. Sharma, 2010, Proanthocyanidins inhibit in vitro and in vivo growth of human non-small cell lung cancer cells by inhibiting the prostaglandin E(2) and prostaglandin E(2) receptors, Mol Cancer Ther, 9, 569, 10.1158/1535-7163.MCT-09-0638 · DOI
  16. Singh, 2011, Grape proanthocyanidins induce apoptosis by loss of mitochondrial membrane potential of human non-small cell lung cancer cells in vitro and in vivo, PLoS One, 6, e27444, 10.1371/journal.pone.0027444 · DOI
  17. Nomoto, 2004, Chemoprevention of colorectal cancer by grape seed proanthocyanidin is accompanied by a decrease in proliferation and increase in apoptosis, Nutr Cancer, 49, 81, 10.1207/s15327914nc4901_11 · DOI
  18. Chen, 2014, Grape seed proanthocyanidins (GSPs) inhibit the growth of cervical cancer by inducing apoptosis mediated by the mitochondrial pathway, PLoS One, 9, e107045, 10.1371/journal.pone.0107045 · DOI
  19. Vaid, 2011, Grape seed proanthocyanidins inhibit melanoma cell invasiveness by reduction of PGE2 synthesis and reversal of epithelial-to-mesenchymal transition, PLoS One, 6, e21539, 10.1371/journal.pone.0021539 · DOI
  20. Engelbrecht, 2007, Proanthocyanidin from grape seeds inactivates the PI3-kinase/PKB pathway and induces apoptosis in a colon cancer cell line, Cancer Lett, 258, 144, 10.1016/j.canlet.2007.08.020 · DOI
  21. Nandakumar, 2008, Multi-targeted prevention and therapy of cancer by proanthocyanidins, Cancer Lett, 269, 378, 10.1016/j.canlet.2008.03.049 · DOI · Paper page
  22. Ting-Ting, 2012, Inhibitive effect of proanthocyanidins on cyclooxygenase-2 expression in A549 cells induced by cytokine interleukin-1 beta, J Shanghai Jiaotong Univ, 17, 500, 10.1007/s12204-012-1312-y · DOI
  23. Jayaprakasha, 2006, Phenolic constituents in the fruits of Cinnamomum zeylanicum and their antioxidant activity, J Agric Food Chem, 54, 1672, 10.1021/jf052736r · DOI
  24. Dall'Acqua, 2009, Phytochemical composition and antioxidant activity of Laurus nobilis L, leaf infusion J Med Food, 12, 869, 10.1089/jmf.2008.0119 · DOI
  25. Taher, 2006, Majid F adibah abdul and Sarmidi MRS: A proanthocyanidin from cinnamomum zeylanicum stimulates phosphorylation of insulin receptor in 3t3-l1 adipocytes, J Teknol, 44, 53
  26. Bouaziz, 2007, Cinnamtannin B-1 from bay wood reduces abnormal intracellular Ca2+ homeostasis and platelet hyperaggregability in type 2 diabetes mellitus patients, Arch Biochem Biophys, 457, 235, 10.1016/j.abb.2006.10.020 · DOI
  27. Ben Amor, 2007, Characterization of the intracellular mechanisms involved in the antiaggregant properties of cinnamtannin B-1 from bay wood in human platelets, J Med Chem, 50, 3937, 10.1021/jm070508d · DOI
  28. Bouaziz, 2007, Cinnamtannin B-1 from bay wood exhibits antiapoptotic effects in human platelets, Apoptosis, 12, 489, 10.1007/s10495-006-0014-z · DOI
  29. Wen, 2015, Identification of phenolics in litchi and evaluation of anticancer cell proliferation activity and intracellular antioxidant activity, Free Radic Biol Med, 84, 171, 10.1016/j.freeradbiomed.2015.03.023 · DOI
  30. Kashiwada, 1992, Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents, J Nat Prod, 55, 1033, 10.1021/np50086a002 · DOI
  31. Chou, 1983, Analysis of combined drug effects: A new look at a very old problem, Trends Pharmacol Sci, 4, 450, 10.1016/0165-6147(83)90490-X · DOI
  32. Chou, 1984, Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, 22, 27, 10.1016/0065-2571(84)90007-4 · DOI · Paper page
  33. Chou, 2010, Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res, 70, 440, 10.1158/0008-5472.CAN-09-1947 · DOI · Paper page
  34. Kelly, 2007, Chemotherapy in metastatic colorectal cancer, Surg Oncol, 16, 65, 10.1016/j.suronc.2007.04.006 · DOI
  35. Chibaudel, 2012, Therapeutic strategy in unresectable metastatic colorectal cancer, Ther Adv Med Oncol, 4, 75, 10.1177/1758834011431592 · DOI
  36. Goodwin, 2009, Overview of systemic therapy for colorectal cancer, Clin Colon Rectal Surg, 22, 251, 10.1055/s-0029-1242465 · DOI
  37. Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  38. Abraha, 2016, Apoptotic pathways as a therapeutic target for colorectal cancer treatment, World J Gastrointest Oncol, 8, 583, 10.4251/wjgo.v8.i8.583 · DOI
  39. Lane, 1992, Cancer. p53, guardian of the genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
  40. Higashimoto, 2000, Human p53 is phosphorylated on serines 6 and 9 in response to DNA damage-inducing agents, J Biol Chem, 275, 23199, 10.1074/jbc.M002674200 · DOI
  41. Kaeser, 2004, Regulation of p53 stability and function in HCT116 colon cancer cells, J Biol Chem, 279, 7598, 10.1074/jbc.M311732200 · DOI
  42. Schuler, 2000, p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release, J Biol Chem, 275, 7337, 10.1074/jbc.275.10.7337 · DOI
  43. Soussi, 2006, Locus-specific mutation databases: Pitfalls and good practice based on the p53 experience, Nat Rev Cancer, 6, 83, 10.1038/nrc1783 · DOI
  44. Siegel, 2014, Cancer Stat, 2014, 9
  45. Hemann, 2006, The p53-Bcl-2 connection, Cell Death Differ, 13, 1256, 10.1038/sj.cdd.4401962 · DOI
  46. Al-Suhaibani, 2015, Antiproliferation and antiactivity of proanthocyanidins against colorectal cancer cells (Caco-2) line through mitochondrial pathway, Int J Adv Sci Tech Res, 4, 152
  47. Roy, 2005, Grape seed proanthocyanidins induce apoptosis through p53, Bax, and caspase 3 pathways, Neoplasia, 7, 24, 10.1593/neo.04412 · DOI
  48. Liu, 2006, Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines, Proc Natl Acad Sci USA, 103, 976, 10.1073/pnas.0510146103 · DOI · Paper page
  49. Yoo, 2007, Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication, PLoS One, 2, e1112, 10.1371/journal.pone.0001112 · DOI
  50. Sun, 2009, To C or not to C: Direct and indirect redox regulation of Src protein tyrosine kinase, Cell Cycle, 8, 2353, 10.4161/cc.8.15.9225 · DOI
  51. Vaughn, 2008, Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrom c, Nat Cell Biol, 10, 1477, 10.1038/ncb1807 · DOI
  52. Salvioli, 2003, Apoptosis-resistant phenotype in HL-60-derived cells HCW-2 is related to changes in expression of stress-induced proteins that impact on redox status and mitochondrial metabolism, Cell Death Differ, 10, 163, 10.1038/sj.cdd.4401124 · DOI
  53. Mileo, 2016, Polyphenols as modulator of oxidative stress in cancer disease: New therapeutic strategies, Oxid Med Cell Longev, 2016, 6475624, 10.1155/2016/6475624 · DOI
  54. Cos, 2004, Proanthocyanidins in health care: Current and new trends, Curr Med Chem, 11, 1345, 10.2174/0929867043365288 · DOI
  55. Lee, 2012, Wogonin induces apoptosis by activating the AMPK and p53 signaling pathways in human glioblastoma cells, Cell Signal, 24, 2216, 10.1016/j.cellsig.2012.07.019 · DOI
  56. Sharif, 2010, Red wine polyphenols cause growth inhibition and apoptosis in acute lymphoblastic leukaemia cells by inducing a redox-sensitive up-regulation of p73 and down-regulation of UHRF1, Eur J Cancer, 46, 983, 10.1016/j.ejca.2009.12.029 · DOI
  57. Shankar, 2007, Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer, Int J Oncol, 30, 905
  58. Ye, 2004, The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX, DNA Repair (Amst), 3, 235, 10.1016/j.dnarep.2003.10.014 · DOI
  59. Su, 2006, Curcumin-induced apoptosis of human colon cancer colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3, Anticancer Res, 26, 4379
  60. Méplan, 2000, Redox signalling and transition metals in the control of the p53 pathway, Biochem Pharmacol, 59, 25, 10.1016/S0006-2952(99)00297-X · DOI
  61. Maillet, 2012, Redox regulation of p53, redox effectors regulated by p53: A subtle balance, Antioxid Redox Signal, 16, 1285, 10.1089/ars.2011.4434 · DOI
  62. Liu, 2008, ROS and p53: A versatile partnership, Free Radic Biol Med, 44, 1529, 10.1016/j.freeradbiomed.2008.01.011 · DOI

Cited by

Sorted by citations

See all 18

Metadata

Authors
Carriere, P., Kapur, N., Mir, H., Ward, A., & Singh, S.
Affiliations
Morehouse School of Medicine (US)
Corresponding author
Singh, Shailesh
ORCID
Venue
International Journal of Oncology
Publisher
Spandidos Publications
Published
2018-07-19
Volume
53
Issue
4
Pages
1442-1454
ISSN
  • 1019-6439 (ISSN-L)
  • 1791-2423
DOI
10.3892/ijo.2018.4489
PMC
PMC6086629
OpenAlex
W2884690170
Cited by
18
References
2
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 4 · 2020: 4 · 2019: 3
FWCI
1.08
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • International Journal of Oncology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • University of Alabama at Birmingham
  • University of Alabama
  • Morehouse School of Medicine
  • National Institutes of Health (CA118638)
  • National Cancer Institute (CA179701, SC1CA180212, CA169716, CA118638, R21CA169716, U01CA179701, CA180212)
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Tannin, Tannase and Anticancer Activities
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Physical Sciences › Chemistry › Organic Chemistry › Natural product bioactivities and synthesis
Keywords
colon cancer, apoptosis, p53, Bcl-2, Bak, cytochrome c release, cell cycle arrest, 5-fluorouracil, drug synergy, anticancer natural products, DLD-1 cells, HCT116 cells
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Cell Survival, Colonic Neoplasms, Dose-Response Relationship, Drug, Drug Synergism, Fluorouracil, Humans, Treatment Outcome, Apoptosis, Gene Expression Profiling, Proanthocyanidins, Cell Line, Tumor, Apoptosis Regulatory Proteins, Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review